NIH extends agreement with Galapagos until end 2012
(Thomson Reuters ONE) -
Mechelen, Belgium; 12 July 2010 - Galapagos NV (Euronext: GLPG) announced today
that the U.S. National Institutes of Health (NIH) have extended their agreement
with Galapagos' service division BioFocus for the operation of the Molecular
Libraries Small Molecule Repository (MLSMR) through December 2012. According to
the terms of this agreement, Galapagos will be eligible to receive up to $8.6
million (?7.0 million) over the course of the two year extension.
BioFocus runs a compound management facility for a number of industrial and U.S.
government customers out of its Compound Focus, Inc. subsidiary in South San
Francisco. Home to the MLSMR since 2004, this facility acquires and stores
compounds under the NIH contract and distributes these compounds for
high-throughput biological screening throughout the NIH's academic network in
the U.S.
"We are pleased that the NIH has exercised its option to extend its
long-standing collaboration with BioFocus' compound management facility for
another two years. BioFocus has proven that it consistently delivers a
high-quality service across the vast NIH screening center network," said Onno
van de Stolpe, CEO of Galapagos.
About the Molecular Libraries Small Molecule Repository (a Roadmap initiative)
The NIH MLSMR collects samples for high throughput biological screening and
distributes them to the NIH Molecular Libraries Screening Center Network. MLSMR
is a key component of the Molecular Libraries Initiative, a NIH Roadmap project
supporting 'new pathways to discovery in the 21st century'. The project is
funded in whole with U.S. federal funds from the National Institutes of Health,
Department of Health and Human Services, under contract HHS-N-278-2004-41001C
with Compound Focus, Inc.
About BioFocus
BioFocusaims to expand its partners' drug pipelines by accelerating the
gene-to-drug candidate discovery process. This is achieved through a
comprehensive discovery platform, which includes target discovery in human
primary cells, focused as well as diverse compound libraries, in vitro and
cell-based screening, structural biology, medicinal chemistry, ADME/PK services,
supported by unique chemogenomic and informatics tools, and compound library
acquisition, storage and distribution services. As a service division of
Galapagos, BioFocus has over 250 employees based in the UK, the US and
Switzerland. More info at: www.biofocus.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with four clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing alliances with
GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co., Roche and
Servier, Galapagos is eligible to receive ?3.3 billion in downstream milestones,
plus royalties. Together with its BioFocus and Argenta service operations,
Galapagos has over 670 employees and operates facilities in six countries, with
global headquarters in Mechelen, Belgium. More info at: www.glpg.com
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions, performance
or achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
[HUG#1430877]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Galapagos NV via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.07.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 23739
Anzahl Zeichen: 0
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NIH extends agreement with Galapagos until end 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
